Amgen Boosts Growth With Strong Q1 Results and $1.9B Infrastructure Investment

Amgen Inc. (NASDAQ:AMGN) is one of the 15 best stocks to invest in for an 18 year old. Amgen Inc. (NASDAQ:AMGN) highlighted its strong first-quarter results and strategic plans in a presentation at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 on June 10. Strong product performance and innovation drove the company’s reported 9% revenue gain and 24% non-GAAP EPS increase year-over-year.

Amgen Boosts Growth With Strong Q1 Results and $1.9B Infrastructure Investment

360b / Shutterstock.com

The company is making significant strides in its operations, particularly with regard to its current pipeline. Notably, Meritide is currently conducting Phase III studies, and the results will be shared at the ADA convention. While TESPIRE is progressing in other indications and significant PDUFA deadlines are drawing up, the company’s Euplisna was introduced as an FDA-approved treatment for IgG4-related disease.

The company has announced this year that it plans to invest $1 billion in a drug substance plant in North Carolina and an additional $900 million in a completed drug product plant in Ohio as part of its ongoing efforts to develop and grow its network infrastructure.

Amgen Inc. (NASDAQ:AMGN) is a global biopharmaceutical company that focuses on human treatments for cardiovascular, hematology, inflammation, cancer, and bone health.

While we acknowledge the potential of AMGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

Read More: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds

Disclosure: None.